44th Interscience Conference on Antimicrobial Agents and Chemotherapy: An update on new antibiotics, novel non-antibacterial treatment modalities and critical issues in antibiotic resistance

Expert Opinion on Investigational Drugs

Volumn 14, Issue 1, 2005, Pages 93-99

  Alekshun, Michael N ^a  

^a Transcept Pharmaceuticals Inc   (United States)

Author keywords

Anti infection; Antibiotic; Antibiotic development; Antibiotic resistance; CA MRSA; Daptomycin; Linezolid; MRSA; Telavancin; Tigecycline; VRE; VRSA

Indexed keywords

AMPICILLIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BENZALKONIUM CHLORIDE; BETA LACTAM; CHLORHEXIDINE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; NEW DRUG; OPT 80; ORITAVANCIN; PROCAINE PENICILLIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; TOXBLOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK 771;

ABDOMINAL INFECTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIARRHEA; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG RESEARCH; ENZYME DEFECT; HEALTH CARE COST; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA AND VOMITING; NONHUMAN; ORGANIZATION; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISTRICT OF COLUMBIA; DRUG RESISTANCE, MICROBIAL; DRUGS, INVESTIGATIONAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 12744273679     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.1.93     Document Type: Conference Paper

References (45)

1. ALEKSHUN MN: Recent advancements in antibiotic development and discovery. Expert Opin. Investig. Drugs (2005).
2. ALEKSHUN MN, LEVY SB: Targeting virulence to prevent infection: to kill or not to kill? Drug Discov. Today (2004) (In press).
3. SHANGLE S, LEE C, OKUMU F et al.: Safety and pharmacokinetics of OPT-80 in human volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
4. FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
5. FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenoulsy to subjects with renal impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
6. MAHARAJ N, JHA R, CHUGH Y et al.: A phase-I study of escalating single doses of intravenous (IV) WCK 771. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
7. LOVERING AM, BANNISTER GC, MacGOWAN AP: A comparison of the penetration of vancomycin and linezolid into bone. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
8. ZHANEL GG, HOMENUIK K, NICHOL K et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 64(1):63-88.
9. DARTOIS N, GIOUD-PAQUET M, ELLIS-GROSSE EJ, LOH E: Tigecycline versus imipenem/cilastatin for treatment of complicated intra-abdominal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
10. DARTOIS N, GROUP TCS: Results of a Phase III, double-blind, safety and efficacy study comparing tigecycline with vancomycia/aztreonam to treat complicated skin and skin structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
11. HIGGINS DI, CHANG R, DEBABOV DV et al.: Telavancin bactericidal activity against Staphylococcus aureus is mediated by multiple mechanisms. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
12. LANGERMANN S, BABIN M, LEWKOWSKI J, RIDDLE V: Therapeutic potential of dominant negative inhibitor (DNI) following spore challenge in New Zealand white (NZW) rabbits. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
13. FINLAY BB, FALKOW S: Common themes in microbial pathogenicity revisited. Microbiol Mol. Biol. Rev. (1997) 61(2):136-169.
14. GOLDSCHMIDT RM, LOELOFF M, FERNANDEZ J et al.: Identification and characterization of inhibitors of bacterial Type III secretion systems (TTSS) as potentail antimicrobial agents. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
15. LI X, GUAN Q, MacIELAG M et al.: Synthesis and SAR of inhibitors of bacterial Type III protein secretion. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
16. FERNANDEZ J, ABBANAT D, BUSH K et al.: In vivo efficacy of the bacterial Type III protein secretion systems (TTSS) inhibitors JNJ-1025798 and JNJ-10278385. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
17. GALLEGOS M-T, SCHLEIF R, BAIROCH A, HOFMANN K, RAMOS JL: AraC/XylS family of transcriptional activators. Microbiol Mol. Biol. Rev. (1997) 61:393-410.
18. ALEKSHUN MN, BARTLETT VJ, BOWSER T et al.: Novel anti-infection agents: small molecule transcription factor modulators. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
19. WALBURGER A, KOUL A, FERRARI G et al.: Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science (2004) 304(5678):1800-1804.
20. COWLEY S, KO M, PICK N et al.: The Mycobacterium tuberculosis protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth in vivo. Mol. Microbiol. (2004) 52(6):1691-1702.
21. KLEBL BM, KOUL A, MISSIO A, PIETERS J: Inhibitors of the mycobacterial kinase PknG provide completely new options for the treatment of tuberculosis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
22. GELLER BL, DEERE J, IVERSEN P: Antisense phosphorodiamidate morpholino oligomer inhibits viability Escherichia coli in mouse peritonitis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
23. DAUM R: Methicillin resistant Staphylococcus aureus in the community. infection control strategies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
24. NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. J. Am. Med. Assoc. (2003) 290 22):2976-2984.
25. JERNIGAN J: Methicillin resistant Staphylococcus aureus in the community: infection control strategies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
26. CENTERS FOR DISEASE CONTROL AND PREVENTION: Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53(15):322-323.
27. WHITENER CJ, PARK SY, BROWNE FA et al.: Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. (2004) 38 8):1049-1055.
28. CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene N. Engl. J. Med. (2003) 348(14 ):1342-1347.
29. PÉRICHON B, COURVALIN P: High-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus: lost in transcription? 44th Interscience Conference an Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
30. BOZDOGAN B, EDNIE L, APPLEBAUM PC: Generation of high-level glycopeptide resistant derivatives from VRSA-Hershey. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
31. BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother. (2004) 48(12):4762-4765.
32. REZAI K, QUINN JP, HAYES R, LOLANS V, WEINSTEIN RA: Emergence of daptomycin (D) resistance and treatment failure in 2 cases of S. aureus osteomyelitis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
33. GREEN KA, McGEER A, CHURCH D et al.: Results of twelve years of serveillance in Canadian strains of Streptococcus pneumoniae. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
34. PLETZ MW, McGEE L, JORGENSEN J et al.: Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob. Agents Chemother. (2004) 48 9):3491-3497.
35. MARTYNOVA AV: Epidemiology of fluoroquinolone-resistant isolates of Streptococcus pneumoniae gained at the far east of Russia. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
36. REINERT R, JENKINS S, FARRELL D, PATEL M: Multidrug resistance in Streptococcus pneumoniae: update from PROTEKT. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
37. DESHPANDE LM, MOET GJ, BIEDENBACH DJ, JONES RJ: Antimicrobial resistance and molecular epidemiology of VRE isolates from North America and Europe: a report from the SENTRY antimicrobial surveillance program. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC, USA (2004).
38. GAYNES RP: Overview of Gram-negative nosocomial infections. 44th Interscience Conference an Antimicrobial Agents and Chemotherapy Washington, DC, USA (2004).
39. MOET GJ, STILWELL MG, BIEDENBACH DJ, JONES RJ: Variation in occurrence and resistance (R) trends among community-acquired urinary tract infection (CA-UTI) pathogens in North America (NA), Latin America (LA), and Europe (EU): report form the SENTRY antimicrobial surveillance program (2003). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
40. HEINE HS, BASSETT J, MILLER L: Does Bacillus anthracis (Anthrax) express a β-lactamase? 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
41. RUSSELL AD: Whither triclosan? J. Antimicrob. Chemother. (2004) 53(5):693-695.
42. GOLDSTEIN FW, SORIA C, LY A, KITZIS MD: Very high prevalence of resistance to triclosan and other antiseptics among French glycopeptide intermediate S. aureus (GISA). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
43. MEKA VG, GOLD HS: Antimicrobial resistance to linezolid. Clin. Infect. Dis. (2004) 39(7):1010-1015.
44. LEVY SB: Multidrug resistance - a sign of the times. (1998) 338:1376-1378.
45. LEVIN AS, BARONE AA, PENCO J et al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. (1999) 28(5):1008-1011.